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Objectives The purpose of our study was to assess pulmonary endothelial function by vasodilator response to acetylcholine
(Ach) administered in segmental pulmonary arteries in children with idiopathic pulmonary arterial hypertension
(IPAH). We hypothesized that there was a relationship among pulmonary endothelial response to Ach, severity of
the disease, and clinical outcome.
Background IPAH may be associated with pulmonary endothelial dysfunction; however, data regarding the impact of endo-
thelial dysfunction on severity and prognosis of this disease are limited.
Methods Forty-three children and adolescents (mean age: 10.4  5.5 years) with IPAH were included in the study.
Changes in pulmonary blood flow in response to Ach were determined using intravascular Doppler flow measure-
ments. Pulmonary flow reserve (PFR) was calculated as the ratio of pulmonary blood flow velocity in response to
Ach relative to baseline values.
Results Mean PFR of all patients was 1.58  0.67. Mean follow-up after catheterization was 55.7  41.9 months.
Freedom from serious cardiovascular events (lung transplantation or death) was 83% after 2 years, 76% after
3 years, and 57% after 5 years. PFR was related significantly to World Health Organization functional class.
Receiver-operating characteristic curves revealed a PFR of 1.4 as the best cutoff value. Kaplan-Meier analysis
demonstrated that a PFR of 1.4 was highly predictive for cardiovascular events (log-rank [Mantel Cox]
chi-square: 12.49, p  0.0001).
Conclusions Our study demonstrates a strong relationship between pulmonary endothelial response to Ach and prognosis of
children with IPAH. As an adjunct to the usual testing protocol, this method provides additional information for
therapeutic guidance. (J Am Coll Cardiol 2012;60:157–64) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.010i
m
iPulmonary arterial hypertension (PAH) is a disease of the
small pulmonary arteries characterized by a progressive
increase in pulmonary vascular resistance leading to right
ventricular failure and ultimately death. A diagnosis of
idiopathic PAH (IPAH) is made when no known risk factor
is documented (1). Impairment of endothelial function is
considered to be an important factor in the pathogenesis of
IPAH. Endothelial dysfunction affects the production of
vasoconstrictors (i.e., increases production of endothelin I
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disclose.Manuscript received December 6, 2011; revised manuscript received March 14,
2012, accepted April 10, 2012.and thromboxane) and vasodilators (decreases nitric oxide
[NO] and prostacyclin), leading to pulmonary vasoconstric-
tion (2). In vitro studies have shown that the expression and
release of vasodilators correlates inversely with increased
vascular resistance in PAH, reflecting the clinical relevance
of endothelial dysfunction in these patients (3). An in vivo
method for direct invasive assessment of pulmonary endo-
thelial function has been described previously using the
vasodilator response to acetylcholine (Ach) (4–6), a model
that has been used frequently in adults with coronary artery
disease to predict long-term cardiovascular events (7). Ach
nduces endothelium-dependent relaxation by receptor-
ediated stimulation of endogenous NO; therefore, an
mpaired response reflects endothelial dysfunction (8). How-
ever, endothelium-dependent pulmonary artery relaxation by
Ach has not been investigated systematically in children and
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pothesized that a relationship ex-
isted among pulmonary endothe-
lial response to Ach, severity of the
disease, and clinical outcome in
these patients.
Methods
The study protocol was approved
by the institutional committee on
ethical practice. Forty-three chil-
dren and adolescents (24 girls
[56%], mean age: 10.4  5.5
years) with IPAH undergoing
cardiac catheterization to assess
pulmonary hypertension, defined
as mean pulmonary arterial pres-
sure (mPAP) of more than 25
mm Hg, before PAH specific
treatment was initiated, were in-
cluded in the study after informed
written consent was obtained.
Most of these patients belonged to
World Health Organization (WHO) functional class II (n 
23) or class III (n  16). Only 3 patients were in WHO
functional class I, and 2 patients in WHO functional class IV.
Hemodynamic assessment and acute pulmonary vaso-
reactivity testing. Diagnostic cardiac catheterization was
performed under local anesthesia through a percutaneous
femoral approach and was age dependent, with the patients
under conscious sedation using low dosages of midazolam,
benzodiazepine and ketamine, or propofol sedation. Arterial
blood gas measurements were obtained at the beginning,
during, and at the end of each study to exclude carbon
dioxide retention and to document respiratory and meta-
bolic stability throughout the study. Measurements were
performed only when the partial pressure of carbon dioxide
level was between 32 and 45 mm Hg and pH was between
7.35 and 7.45. Measurements of baseline hemodynamics
included mixed venous and arterial saturations, blood gases,
systemic and pulmonary artery pressures, left atrial (or
pulmonary capillary wedge) pressure, and right atrial pres-
sure in the standard manner with fluid-filled catheters.
The assessment of pulmonary vascular reactivity was
carried out as follows. Measurements were obtained at
baseline (as the usual fraction of inspired oxygen), then the
effect of inhaled NO at 40 ppm for 10 minutes was
recorded; after that, the additional effect of oxygen with
fraction of inspired oxygen at approximately 0.8 for 10 min
was assessed. The NO plus additional oxygen then was
discontinued, and new baseline hemodynamics were mea-
sured after 10 min. Subsequently, aerosolized iloprost (0.3
g/kg) was administered by a specific applicator. In awake
children with a chance for active inhalation, iloprost was
Abbreviation
and Acronyms
Ach  acetylcholine
CCB  calcium-channel
blocker therapy
IPAH  idiopathic
pulmonary arterial
hypertension
mPAP  mean pulmonary
arterial pressure
mSAP  mean systemic
arterial pressure
NO  nitric oxide
PA  pulmonary arterial
PAH  pulmonary arterial
hypertension
PFR  pulmonary flow
reserve
ROC  receiver-operating
characteristic
WHO  World Health
Organizationadministered in a total dose of 5 g. Measurements wererepeated after 10 min with a combination of iloprost plus
NO plus oxygen.
Vasodilator response to Ach. Before vasoreactivity testing
was performed with the above-mentioned protocol, pulmo-
nary endothelial function was assessed by vasodilator re-
sponse to Ach. Dependent on the patient size, a 4-F or 5-F
multipurpose catheter was inserted into the left or right
lower lobe pulmonary artery. A 0.014-inch pulsed Doppler
wire (Cardiometrics, Inc., Mountain View, California) was
positioned through the multipurpose catheter into a straight
segment of the medial or posterior branch of the lower lobe
pulmonary artery with a diameter of 3 to 5 mm. The
position of the Doppler wire in the center of this vessel was
confirmed by a hand injection of contrast through a Thouy-
Borst adapter (sighting angiography) (Fig. 1) and a stable
flow-velocity signal with minimal noise (4). Then, serial
infusions were made via the multipurpose catheter into the
segmental pulmonary artery using an infusion pump with
Ach concentrations of 106 M and 105 M, respectively.
Changes in pulmonary blood flow in response to Ach were
assessed using intravascular Doppler blood flow velocity
measurements. Pulmonary flow reserve (PFR) was calcu-
lated as the ratio of pulmonary blood flow velocity in
response to Ach relative to baseline values.
Statistical analysis. Data are presented as mean  SD.
Correlations were obtained by Pearson’s correlation test. To
compare PFR values of patients with different clinical status,
we used the unpaired nonparametric Mann-Whitney U test.
A receiver-operating characteristic (ROC) curve was used to
identify the best threshold value (maximum sensitivity and
specificity) for prediction of serious cardiovascular events,
defined as lung transplantation or death. Freedom from
serious cardiovascular events after catheterization was illus-
trated by Kaplan-Meier curves, and outcomes were com-
pared using the log-rank test. Statistical analysis was per-
formed using IBM (IBM Corp., Armonk, New York) SPSS
Statistics software version 19.0 (SPSS, Inc., Chicago, Illi-
nois). The null hypothesis was rejected when p  0.05.
Results
Among the 43 patients, the mean mPAP-to-mSAP ratio
was 0.89  0.28, reflecting the severity of PAH. Twenty-
one (49%) of the 43 patients showed an acute response to
global vasoreactivity testing defined as a 20% reduction in
the mPAP-to-mSAP ratio. The mean reduction of the
mPAP-to-mSAP ratio was 30  18.2%. Mean cardiac
index increased from 3.0  0.9 l/min/m2 to 3.8  1.6
l/min/m2.
Baseline mPAP was 67.1  19.1 mm Hg, and minimum
mPAP during vasoreactivity testing was 50.9  23.9 mm Hg.
The mean change in mPAP during vasoreactivity testing
was 26.9  19.3%. Twenty-five of the 43 patients showed a
more than 20% reduction of the mPAP, 18 of them to a
mPAP of 40 mm Hg. Basal mean indexed pulmonary
vascular resistance was 23.5  12.6 Wood units/m2 body
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cular resistance during vasoreactivity testing was 16.2 
11.2 Wood units/m2 body surface area.
The mean baseline flow velocity in the segmental pulmo-
nary artery of all patients was 18.1  9.7 cm/s. During Ach
infusion, the mean flow velocity increased to 30.6  25.5
cm/s (p  0.0001). The calculated mean PFR was 1.58 
0.67.
PFR correlated well with maximum percentage decrease
in the ratio of mPAP to mSAP during vasoreactivity testing
(r  0.61, p  0.0001) (Fig. 2A). There was an inverse
Figure 1 Sighting Angiography
Hand injection of contrast through a Thouy-Borst adapter to confirm position of
the Doppler wire in the center of the vessel: (A) anteroposterior projection, (B)
lateral projection. The wire was inserted via a multipurpose catheter into the
left lower lobe pulmonary artery.orrelation between PFR and minimum mean PA pressureuring vasoreactivity testing (r  0.45, p  0.003)
Fig. 2B) and between PFR and minimum mean indexed
ulmonary vascular resistance (r0.42, p 0.006) (Fig. 2C);
owever, no significant correlation between basal pulmo-
Figure 2 Relationship Between Pulmonary Flow Reserve
and Results of Pulmonary Vasoreactivity Testing
(A) Pulmonary flow reserve (PFR) correlated well with maximum percentage
decrease in the ratio of mean pulmonary arterial pressure (mPAP) to mean sys-
temic arterial pressure (mSAP) during vasoreactivity testing, assessed as:
1  [minimum (mPAP/mSAP)/baseline (mPAP/mSAP)] (r  0.61; p  0.0001).
There was an inverse correlation (B) between PFR and minimum mPAP during
vasoreactivity testing (r  0.45, p  0.003) and (C) between PFR and mini-
mum mean indexed pulmonary vascular resistance (minimum PVRI)
(r  0.42, p  0.006).
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 0.05).
Mean follow-up after catheterization was 55.7  41.9
onths. Freedom from serious cardiovascular events (de-
ned as lung transplantation or death) after catheterization
as 83% after 2 years, 76% after 3 years, and 57% after 5
ears (Fig. 3).
To investigate the predictive value of PFR, we performed
OC curve analysis, which discriminated a PFR of 1.4 as
he best cutoff value (area under the ROC curve: 0.753, 95%
onfidence interval: 0.602 to 0.905, sensitivity: 0.67, speci-
city: 0.875, p  0.006). The PFR was less than 1.4 in 23
f 43 patients. The ROC curve analysis also was performed
or reduction of mPAP-to-mSAP ratio and revealed a
eduction of mPAP-to-mSAP ratio of 30% as the best
utoff value (area under the ROC curve: 0.753, 95%
onfidence interval: 0.603 to 0.904, sensitivity: 0.63, speci-
city: 0.81, p  0.006) (Fig. 4).
PFR correlated inversely with the patient age (r0.33,
 0.01), demonstrating that younger patients are more
ikely to have a higher PFR. In addition, PFR correlated
ith WHO functional class. Patients with a better clinical
tatus showed a higher PFR. A PFR of 1.4 was repre-
ented more frequently in WHO classes III and IV. PFR
as able to differentiate between patients in WHO class II
nd class III (p  0.04), who reflected most of our patients
Fig. 5).
Calcium-channel blocker therapy (CCB) was started
fter the initial catheterization in all 21 responders to the
Figure 3 Freedom From Serious Cardiovascular Events
(Transplantation or Death) After Catheterization
Mean follow-up after catheterization was 55.7  41.9 months. Kaplan-Meier
curve showing freedom from serious cardiovascular events (transplantation or
death) after catheterization was 83% after 2 years, 76% after 3 years, and
57% after 5 years.[asoreactivity testing, in accordance with the current IPAH
uidelines. After 1 year of CCB treatment, in 9 of the 21
esponders, an add-on therapy was necessary or the treat-
ent strategy had to be modified because of clinical wors-
ning. The remaining 12 patients showed a favorable
ong-term response to CCB therapy. The mean PFR within
he group of good responders to CCB therapy was not
ignificantly higher compared with that of patients who
eeded therapy modification (p  0.07) (Fig. 6); however,
nly 3 of 12 patients in the CCB responder group had a
FR of 1.4, compared with 6 of 9 in the therapy failure
roup.
Within the subset with long-term response to CCB, all 9
atients with a PFR of more than 1.4 had a decreased PA
ressure of 40 mm Hg. There was an inverse correlation
etween PFR and minimum mean PA pressure during vaso-
eactivity testing (r  0.45, p  0.003).
To evaluate the prognostic value, we compared the follow-
ng parameters using Kaplan-Meier analysis: reduction in
PAP-to-mSAP ratio of more than 20%, reduction in
PAP-to-mSAP ratio of more than 30%, decrease in mPAP
f 40 mm Hg, and PFR of more than 1.4 (Fig. 7). All of
hese parameters have an impact on prognosis of patients
ith IPAH; however, PFR of more than 1.4 was most
redictive for long-term cardiovascular events (log-rank
Figure 4
ROC Curves for the Sensitivity and Specificity of
PFR and Decrease of the Ratio of mPAP to mSAP
During Vasoreactivity Testing Regarding the
Prediction of Serious Cardiovascular Events
Receiver-operating characteristic (ROC) curve analysis discriminated a PFR of
1.4 as the best cutoff value (area under the ROC curve: 0.753, 95% confi-
dence interval: 0.602 to 0.905, sensitivity: 0.67, specificity: 0.875, p 
0.006). In addition, ROC curve analysis revealed a reduction of the mPAP-to-
mSAP ratio of 30% as the best cutoff value (area under the ROC curve: 0.753,
95% confidence interval: 0.603 to 0.904, sensitivity: 0.63, specificity: 0.81,
p  0.006). Abbreviations as in Figure 2.Mantel Cox] chi-square: 12.49, p  0.0001).
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In this study, we demonstrated that the pulmonary endo-
thelial function test using the vasodilator response to Ach
administered in a segmental pulmonary artery had consid-
erable prognostic value in children and adolescents with
IPAH. An impaired Ach response, defined as PFR of less
than 1.4 (an increase of flow velocity of less than 40%), was
a strong predictor for poor prognosis in this patient group.
The diagnostic work-up of patients with IPAH is exten-
sive and challenging (9). Cardiac catheterization is still
required for confirming the diagnosis and for guiding
management of the disease (10–12). Acute testing of
vasoreactivity during catheterization is an important factor
in the evaluation of PAH (13,14). However, although the
presence of an acute response has important clinical conse-
quences, its definition remains controversial. In interna-
tional guidelines, the criteria of Sitbon et al. (15) currently
are recommended for adult PAH patients. These criteria
include a decrease in mPAP of 10 mm Hg or more,
reaching an mPAP value of 40 mm Hg or less with an
increased or unchanged cardiac output. In children, the
criteria of Barst et al. (16) generally are used, which include
a decrease in mPAP or in mPAP-to-mSAP ratio of 20% or
more, with an increased or unchanged cardiac output and
unchanged or decreased pulmonary-to-systemic vascular
resistance ratio. Recently, it has been shown that the impact
of an acute response as a prognostic tool in PAH patients
seems to be limited (17). One reason may be that because of
the use of different response criteria, study data are difficult
to compare. In our study, we compared the Barst et al. (16)
criteria and the Sitbon et al. (15) criteria with vasodilator
response to Ach. In addition, we used a ROC analysis to
Figure 5 Relationship Between PFR and
World Health Organization Functional Class
Bar graph showing that patients with better clinical status had higher PFR (
SEM). A PFR of 1.4 was represented more frequently in World Health Organi-
zation (WHO) classes III and IV. PFR was able to differentiate between patients
in WHO class II and those in WHO class III (p  0.04), who comprised most of
our patients. Other abbreviation as in Figure 2.demonstrate that a stricter definition of the Barst et al. (16)criteria with a decrease in mPAP-to-mSAP ratio of 30% or
more may be more reliable to predict outcome in IPAH
patients. According to our data, vasodilator response to Ach is
a strong predictor of prognosis in patients with IPAH. Because
the usual vasoreagibility test reflects the more global response
of the entire pulmonary vessel system, making it more sensitive
to other potential influencing factors, the response to Ach
represents the local segmental vessel endothelial response.
Therefore, our results confirmed the clinical relevance of
endothelial dysfunction in these patients (18).
Vasodilator response to Ach in segmental pulmonary
arteries has been reported previously in children with
congenital heart disease. In 1993, Celermajer et al. (4)
demonstrated that the maximal increase of flow velocity in
pulmonary arteries in response to Ach in children with
normal pulmonary hemodynamics is usually approximately
90% of the baseline value. Patients with pulmonary vascular
disease showed an impaired response with a reduced in-
crease of flow velocity of 50%. However, in this previous
proof-of-principle study, only 2 patients with IPAH were
included. Our recent data confirmed, in a relatively large
cohort of pediatric patients with IPAH, this impaired
response to Ach. In addition, we were able to show that this
parameter has a high impact on diagnosis and prognosis in
these patients. Patients lacking a response to Ach seem to
have a poor prognosis and a rapid progress of the disease,
despite currently available therapeutic options. At this
disease stage, pre-capillary vessels may be engaged by matrix
and adventitial proliferation in which the endothelium may
Figure 6 Relationship Between PFR and
Response to Calcium Channel Blocker Therapy
After 1 year of calcium channel blocker (CCB) treatment, in 9 of the 21
responders, add-on therapy was necessary or treatment strategy has to be
modified because of clinical worsening. The remaining 12 patients showed a
favorable long-term response to CCB therapy. This bar graph demonstrates that
the PFR within the group of good responders to CCB therapy was not signifi-
cantly higher compared with patients who needed therapy modification
(p  0.07). Abbreviation as in Figure 2.
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chance for vasodilation (19).
In our study, we assessed only the vasodilating effect of
Ach. It is possible that other locally administered vasodila-
tors (i.e., nitroprusside) also would be able to predict
outcome. However, Celermajer et al. (4) were able to show
that vasodilation was greater in response to Ach than to
Figure 7 Freedom From Long-Term Cardiovascular Events: Impa
Comparison of the prognostic value of the parameters (A) reduction of mPAP-to-m
(C) decrease of mPAP of less than 40 mm Hg, and (D) PFR of more than 1.4 usin
prognosis of patients with idiopathic pulmonary arterial hypertension. However, PF
[Mantel Cox] chi-square: 12.49, p  0.0001). Abbreviations as in Figure 2.nitroprusside. This may be because for nitroprusside, thedose range is limited by its powerful systemic vasodilator
effect. When we measured the PFR during inhalation of
NO, no significant changes of flow velocities were observed.
One might expect an inverse relation between vessel diam-
eter and change in velocity, and the same change in absolute
flow could lead to a greater change in velocity, and therefore
PFR, in a smaller vessel. With respect to this physiological
f PFR and Results of Pulmonary Vasoreactivity Testing
tio of more than 20%, (B) reduction of mPAP-to-mSAP ratio of more than 30%,
lan-Meier analysis demonstrates that all of these parameters have an impact on
ore than 1.4 was most predictive for long-term cardiovascular events (log-rankct o
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of diameter, no relation between vessel size, basal flow velocity
(r  0.12, p  0.64), and change in velocity related to
absolute flow (r 0.38, p 0.13) was observed. To minimize
his potential limitation on the results, only relative changes,
ather than absolute values, were used in our calculations of
ow velocity, which makes each child its own control. Changes
n relative, rather than absolute, flow velocity also have been
sed by investigators of coronary circulation (7).
Calculation of vascular resistance was based on assumed,
ather than measured, oxygen consumption. The potential
rror thereby introduced can be minimized by using the
p-to-Rs ratio (pulmonary-to-systemic vascular resistance
atio). However, more important for the interpretation of
he vasoreactivity test in IPAH patients is the mPAP or the
PAP-to-mSAP ratio, which is the reason why these
arameters are the most important criteria for vasoreactivity
esting in the current PAH guidelines.
In addition to the prognostic value, vasodilator response
o Ach has an impact on guiding PAH-specific therapy.
ccording to our data, nonresponders to the global vasore-
ctivity testing method can have a positive vasodilator
esponse to Ach, which implies preserved endothelial func-
ion and a more favorable outcome in this group of patients.
hese patients also may show a favorable long-term benefit
o therapy with phosphodiesterase type 5 inhibitors by
obilizing their preserved endogenous NO system. This
ay explain why in some nonresponders, this drug may be
ore effective than in other patients with comparable
egative global acute vasoreactivity test results. In addition,
ual endothelin-receptor antagonists in patients with pre-
erved vasodilator response to Ach should be used with care,
ecause it has to be kept in mind that the potentially
ndogenous vasodilating effect of endothelial endothelin-B
eceptors also will be blocked (20).
Our data demonstrate that endothelium-dependent pul-
onary artery relaxation obviously is age and disease depen-
ent. Younger patients are more likely to have a positive
asodilator response to Ach than older children. An age-
ependent progress of IPAH has been postulated previ-
usly, especially because the frequency of responders to
asoreactivity testing is reported to be significantly higher in
hildren than in adults (15,16,21). Therefore, it has been
peculated that aging may be responsible for a progressive
oss of vascular response to NO and Ach. Continuous shear
tress may induce progress of the disease from the primary
ffected endothelium to a destruction of the complete vessel.
In patients with IPAH showing an acute response during
asoreactivity testing (responders), treatment with CCB is
ecommended, according to the current international guide-
ines (13). There is evidence from previous studies in adult
PAH patients that in some of the responders, the effect of
CB therapy does not persist (15). Published data concern-
ng this issue in children and adolescents do not exist to
ate, and there was no effective tool to evaluate favorableong-term response to CCB therapy in patients with IPAHwho responded to vasoreactivity testing. According to our
results, PFR in response to Ach obviously was higher in
patients with a favorable long-term response to CCB
therapy, information that may help in guiding PAH-specific
therapy. Interestingly, we found that within the subset of
patients who demonstrated a long-term response to CCB, all
9 patients with a PFR of more than 1.4 had a decreased PA
pressure of 40 mm Hg, a parameter that was suggested by
Sitbon et al. (15) to predict favorable long-term response in
adults. We also demonstrated an inverse correlation between
PFR and minimum mean PA pressure during vasoreactivity
testing, which suggests that decreasing mean PA pressure to
40 mm Hg also may be a reliable predictor of long-term
response to CCB in children with IPAH and may even be a
surrogate for preserved endothelial function.
Conclusions
We conclude that assessment of endothelium-dependent
pulmonary artery relaxation as an adjunct to the usual
testing protocol provides additional information and has
diagnostic and prognostic implications in patients with
IPAH, and also may guide the decision making for initia-
tion of a specific therapy. Our study demonstrates an
impaired vasodilator response to Ach in segmental pulmo-
nary arteries in most children and adolescents with IPAH,
reflecting pulmonary endothelial dysfunction. An impaired
Ach response was a strong predictor for poor prognosis.
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